Skip to main content
Friday 11 July 2025
BlueSky linkedin youtube rss
User account menu
  • Subscribe
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Commercialisation
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO 2025
    • BIO 2025
    • Axtria Ignite 2025
    • LS Industry Report 2025
    • Frontiers Health 2024
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
BlueSky linkedin youtube rss
Sign in

Eye on ESMO 2016

Views & Analysis
Kantar ESMO Main
profile-mask
Adam Jeffery
8 October, 2016

2016

FacebookXLinkedin
Bookmark this

News
Just how radical is the FDA's complete response letter move?

Just how radical is the FDA's complete response letter move?

The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Market Access
Bridging research and clinical guidelines
Sponsored

Bridging research and clinical guidelines – interactive stra...

Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.

R&D
Deep Dive's research and development 2025 edition out now banner

Deep Dive: Research and Development 2025

Every breakthrough in medicine, every new treatment that changes lives, starts with research. 

R&D
Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Oncology
pharmaphorum podcast Episode 190a, Greg Piefer

On nuclear medicine and oncology, SHINE technologies

Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.

Oncology
Life Sciences Industry Report - Part 5 feature image

Life Sciences Industry Report - Oncology

Developments in the oncology space in 2024 brought hope to both industry and patients.

R&D
16th World ADC San Diego 2025
Partner Content

16th World ADC San Diego 2025

The World’s Largest, Longest-Standing & Most Comprehensive Antibody-Drug Conjugate Conference

Digital
New Jersey skyline
Partner Content

Axtria Ignite 2025: Leading in an Agentic Era

Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This

 
 

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

2016

breakthough

Cancer

clinical trial

ESMO

immuno-oncology

Oncology

patient

Pharma

treatment

Category : Views & Analysis /

Editor's Picks

  1. AbbVie's $2.1bn buy of Capstan lifts its immunology pipeline
  2. Summit climbs on rumour of $15bn AstraZeneca interest
  3. The NHS 10 Year Plan arrives – what are the highlights?
  4. Shionogi puts up to $600m behind BioVersys antibiotics
  5. The US Senate has passed Trump's budget – what comes next?
News
Just how radical is the FDA's complete response letter move?

Just how radical is the FDA's complete response letter move?

The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.

Market Access
pharmaphorum podcast Episode 178a - Sandra Anderson and Chris Williams, Cencora

The value of a partner, globally and locally

A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • ASCO 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Subscribe
 
 
rss youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2025, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company